-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Alnylam Pharmaceuticals, Lowers Price Target to $315

Benzinga·08/04/2026 15:28:46
語音播報
Truist Securities analyst Danielle Brill maintains Alnylam Pharmaceuticals (NASDAQ:ALNY) with a Buy and lowers the price target from $410 to $315.